Project description
Early detection of cancer with a single blood sample
Early and equitable detection and treatment are essential for cancer patients. For many types of cancer, no early, equal-access detection methods exist, posing a growing burden on healthcare systems and society. The EU-funded DeteCTCs project aims to provide a fast-track market introduction for the CellMate® innovation, aiming to improve the standard of care for cancer patient diagnosis and treatment. Combining the advanced universal circulating cancer cell capture and recognition technology, DNA sequencing and AI-powered bioinformatics, CellMate® detects multiple types of cancer at an early stage with just one blood draw. The human and economic value of the technology has been demonstrated in studies on breast, ovarian and pancreatic cancer.
Objective
With over 10M deaths and an annual cost of €199B, cancer poses an immense burden on individuals, healthcare, and society. To reduce cancer deaths, improve patients’ quality of life, and lower the economic cost, both early detection and treatment are key. Current methods for early cancer screening and minimal residual disease (MRD) testing include inconvenient and costly procedures such as mammograms, Pap smears, colonoscopies. Unfortunately, for the majority of cancers, no early detection method exists. Blood-based tests offer an attractive opportunity and receive major interest from the industry. Yet, no FDA-approved test for blood-based early cancer detection and MRD testing exists. The novel tests in development, focus on circulating tumor DNA detection. This is limited by low sensitivity, thus lacking clinical validity and utility.
The breakthrough CellMate® innovation, fast-tracked to market entry in this FTI project, will fundamentally transform the standard of care for cancer detection. Incorporating the advanced IsoPic™ universal circulating tumor cell capturing, staining technology, and AI-powered bioinformatics workflow, CellMate® detects multiple types of early-stage cancer and MRD with 90% sensitivity. Additionally, the AI-driven decision support functionality enables informed clinical decisions, including personalized treatment suggestions. Based on only a single blood draw, the molecular details of the cancer are provided in 4 days. Technology partners iCellate and QIAGEN (global leader in bioinformatic analysis) team-up with UKSH, a leading oncology institute in Europe. Together we demonstrate CellMate®’s clinical and economic value in a study with breast, ovarian, and pancreatic patients. The extensive network of our consortium ensures a broad outreach to patients, clinicians, healthcare organizations. CellMate® benefits from a multi-billion-euro (>€2.2B) market opportunity that is growing with the cancer screening market rising to ~9B by 2030.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
This project's classification has been validated by the project's team.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
This project's classification has been validated by the project's team.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EC - Horizon 2020 Framework Programme
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
IA - Innovation action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-FTI-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
23562 Lübeck
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.